| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 411.0 | 387.8 | 353.0 |
| Other income | 10.6 | 9.1 | 12.8 |
| Total income | 421.6 | 397.0 | 365.8 |
| Profit before exceptional items & tax | 50.6 | 66.0 | 61.7 |
| Exceptional items | 0.0 | 1.5 | 0.0 |
| Profit before tax | 50.6 | 67.6 | 61.7 |
| Net profit | 37.5 | 50.3 | 43.9 |
| Operating margin | 12.0% | 17.0% | 16.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -14.60% |
|---|---|
| Net profit, quarter on quarter | -25.40% |
| Revenue, year on year | +16.40% |
| Operating profit, year on year | -13.50% |
| Operating profit, quarter on quarter | -34.70% |
BSE results filing, NSE: JLHL. Figures extracted from the filing.
Jupiter Life Line Hospitals Ltd: key numbers
- Share price
- ₹250.00
- Market cap
- ₹8,196 Cr
- Revenue (annual)
- ₹1,500 Cr
- Net profit (annual)
- ₹194.0 Cr
- P/E (TTM)
- 43.7×Sector 53.1×
- Promoter holding
- 40.91%+0.00% QoQ
- FII holding
- 9.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jupiter Life Line Hospitals Ltd
All →Jupiter Life Line Hospitals Earnings Call Transcript: Key Takeaways
Management is optimistic as the new Dombivli hospital ramps up, despite it causing a 9.5 crore EBITDA drag this quarter.
Jupiter Life Line Hospitals Other Announcement
Jupiter Life Line Hospitals Limited has authorized specific Key Managerial Personnel for determining and disclosing material events under SEBI Regulation 30(5).
Jupiter Life Line Hospitals Management Change
Jupiter Life Line Hospitals Limited has appointed Mr. Harshad Gaurishankar Purani as the new Chief Financial Officer, effective July 31, 2026.
Jupiter Life Line Hospitals Merger & Restructuring Worth ₹3.78 Cr
Jupiter Life Line Hospitals' subsidiary, Jupiter Hospital Pharmacy, acquired 100% of Sulcus Private Limited for ₹3.78 Crore. This move aims to expand pharmaceutical manufacturing capabilities.
- Value
- ₹3.78 Cr
Jupiter Life Line Hospitals Investor Presentation: Key Takeaways
Jupiter Life Line Hospitals reported Q1FY27 revenue growth of 16.2% YoY, while PAT declined 14.7% due to higher depreciation and finance costs from the new Dombivli facility.
Jupiter Life Line Hospitals Share Pledge
Catalyst Trusteeship Ltd disclosed the creation of a pledge over 1,67,59,750 equity shares of Jupiter Life Line Hospitals Ltd.